Sugi Predict

Sugi Predict / Compounds / SCHEMBL400760

SCHEMBL400760

SCHEMBL400760

COC(=O)c1cccc(Cl)c1C#N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 2/20 0.48
▸ LMNA P02545 4/20 0.44
▸ TSHR P16473 1/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ NOTUM Q6P988 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ HPGD P15428 3/20 0.43
▸ CFTR P13569 1/20 0.43
▸ MAPT P10636 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ POLB P06746 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ CYP1A2 P05177 2/20 0.41
▸ PKM P14618 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL109089 0.83 TSHR (0.54) TSHRNOTUMALDH1A1KDM4EHSD17B10
SCHEMBL2949430 0.81 LMNA (0.59) LMNATSHRALDH1A1KDM4EHSD17B10
SCHEMBL6332331 0.81 ALDH1A1 (0.48) NR4A2LMNATSHRALDH1A1KDM4E
SCHEMBL23754038 0.80 KDM4E (0.43) NR4A2LMNATSHRALDH1A1KDM4E
SCHEMBL4825801 0.80 LMNA (0.44) LMNATSHRSLC6A3ALDH1A1KDM4E
SCHEMBL1478814 0.80 ALDH1A1 (0.50) LMNATSHRSLC6A3ALDH1A1KDM4E
SCHEMBL22996549 0.80 ALDH1A1 (0.61) LMNATSHRALDH1A1KDM4EHSD17B10
SCHEMBL16961195 0.80 ALDH1A1 (0.47) LMNATSHRALDH1A1KDM4EHSD17B10
SCHEMBL109282 0.79 TSHR (0.57) LMNATSHRNOTUMALDH1A1KDM4E
SCHEMBL20660599 0.79 ALDH1A1 (0.46) LMNANOTUMALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008096371-A1 ISOINDOLINONE PIGMENTS AND A METHOD OF MANUFACTURING. SUDARSHAN CHEMICAL INDUSTRIES LTD. (IN) 2008-08-14 — — WO claimed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 — — EP disclosed
CN-119874700-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2025-04-25 — — CN disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 — — US disclosed
CN-114945366-B HPK1 antagonists and uses thereof 林伯士萨顿公司 2025-01-07 — — CN disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 — — US disclosed
CN-108250159-B Urea compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-07-11 — — CN disclosed
US-11548890-B1 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2023-01-10 — — US disclosed
US-20150025075-A1 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2015-01-22 — — US disclosed
EP-2804865-A1 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2014-11-26 — — EP disclosed
CN-104066737-A As P2X7Heterocyclic amide derivatives of receptor antagonists ACTELION PHARMACEUTICALS LTD 2014-09-24 — — CN disclosed
CN-103429582-A MST1 kinase inhibitors and method of use thereof LEXICON PHARMACEUTICALS INC 2013-12-04 — — CN disclosed
EP-2017279-B1 AMINOPYRIMIDINE DERIVATIVES HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY MSD KK (JP) 2013-09-04 — — EP disclosed
WO-2013108227-A1 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2013-07-25 — — WO disclosed
US-8101621-B2 Aminopyridine derivatives having aurora a selective inhibitory action MSD K.K. (JP) 2012-01-24 — — US disclosed
US-20090192174-A1 Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-07-30 — — US disclosed
EP-2017279-A1 NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-01-21 — — EP disclosed
WO-2008096371-A1 ISOINDOLINONE PIGMENTS AND A METHOD OF MANUFACTURING. SUDARSHAN CHEMICAL INDUSTRIES LTD. (IN) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548890-B1 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 NR4A2 3300/4885LMNA 3355/4885TSHR 4353/4885
US-20150025075-A1 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS P2RX7, P2RX1, P2RX3 NR4A2 303/4885LMNA 2291/4885TSHR 444/4885
US-20090192174-A1 Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action RB1, AURKA, AURKC NR4A2 407/4885LMNA 2184/4885TSHR 2388/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 NR4A2 3300/4885LMNA 3355/4885TSHR 4353/4885
US-12215105-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 NR4A2 3300/4885LMNA 3355/4885TSHR 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.